Noveris Health Sciences Inc. Restores Trading and Expands Market Operations
Trading Resumption
On April 21 , 2026, Noveris Health Sciences Inc. (ticker 0NF1) was reinstated on the Frankfurt Xetra trading platform. The resumption took effect at 16:10 CET, allowing investors to re-enter positions in the company’s shares. The decision was announced in a formal statement issued by the firm, confirming that all regulatory requirements for trading have been satisfied.
Market‑Making Advisory Agreement
Two days later, on April 22 , 2026, the company entered into a market‑making advisory agreement with DS Market Solutions Inc. The contract is intended to enhance the liquidity of Noveris shares by engaging a specialist advisory service. While the terms of the agreement were not disclosed, the partnership signals the company’s commitment to maintaining orderly market conditions and improving trade execution for shareholders.
Clarifying Release on Life Offering
On April 20 , 2026, Noveris Health Sciences issued a clarifying release concerning its life offering and other disclosure matters. The statement addressed questions raised by investors about the company’s recent offering and reaffirmed compliance with applicable disclosure rules. No material changes to the company’s financial position or strategic direction were announced in this release.
Company Context
Noveris Health Sciences Inc. is listed on the Canadian National Stock Exchange and operates within the consumer staples sector, focusing on food products. The firm is known for providing turnkey growing infrastructure and services to licensed growers and processors of luxury marijuana crops, primarily through its agri‑campuses in Washington State. As of April 21 , 2026, the share price closed at CAD 1.95, with a 52‑week high of CAD 2.35 (March 18 , 2026) and a 52‑week low of CAD 0.12 (October 20 , 2025). The market capitalization stands at approximately CAD 107.6 million, and the price‑to‑earnings ratio is 1.055.
